EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations

Elizabeth D Auckley iD, Stephanie Yohay, Grace Ying, Aniko Szabo iD, Jacquelyn Wittmann, Justin Grahl, Mohammed Aldakkak iD, Samih Z Thalji iD, Thomas McFall iD, Razelle Kurzrock iD, Ben George, Mandana Kamgar

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag040 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Elizabeth D Auckley und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is often caused by mutations in multiple genes, including KRAS (activating the Ras-Raf-MEK-ERK pathway). This study evaluated the role of MEK inhibitor (MEKi)–based combinatorial targeted therapies in patients with PDAC.

Methods

This is a retrospective/prospective observational, single-institution study, including 29 patients with metastatic PDAC with KRAS alterations, treated with MEKi therapies between 2022 and 2024.

Results

Ten patients had KRAS G12R (34.5%), ten G12D (34.5%), and nine G12V (31%). The majority of patients received MEKi therapy as third-line and beyond (KRAS G12R/G12D/G12V: 60%/50%/78%, respectively). Median overall survival from MEKi initiation for KRAS G12R/G12D/G12V was 8.2/5.1/4.7 months (P = .5), respectively, and median progression-free survival was 4.4/2.3/1.4 months (P = .11). Six (21%) patients discontinued at least one drug in the treatment combination due to toxicity.

Conclusions

MEKi–based combinatorial therapies had modest disease control in patients with KRAS G12R, and minimal disease control in patients with KRAS G12D/V in the late-line setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)AgedFemaleHumansMaleMiddle AgedMolecular Targeted TherapyMutationNeoplasm MetastasisProspective StudiesRetrospective StudiesPancreas

Stichwörter der Autor:innen

KRASMEK inhibitorspancreatic ductal adenocarcinomatargeted therapy

Substanzen

KRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
  • Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
  • Data Science Institute, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
  • Department of Pharmacy, Froedtert Health, Milwaukee, WI 53226, United States.
  • Department of Surgery, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI 53226, United States.
  • Department of Biochemistry, Medical College of Wisconsin and the LaBahn Pancreatic Cancer Program, Milwaukee, WI 53226, United States.

ORCID-Profile: Elizabeth D Auckley, Aniko Szabo, Mohammed Aldakkak, Samih Z Thalji, Thomas McFall, Razelle Kurzrock

Förderung

  • NCATS NIH HHS

Zitieren

APA

Auckley, E. D., Yohay, S., Ying, G., Szabo, A., Wittmann, J., Grahl, J., Aldakkak, M., Thalji, S. Z., McFall, T., Kurzrock, R., George, B., & Kamgar, M. (2026). MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. The Oncologist. https://doi.org/10.1093/oncolo/oyag040

Vancouver

Auckley ED, Yohay S, Ying G, Szabo A, Wittmann J, Grahl J, et al. MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. The Oncologist. 2026. doi:10.1093/oncolo/oyag040

BibTeX
@article{Auckley2026,
  author = {Auckley, Elizabeth D and Yohay, Stephanie and Ying, Grace and Szabo, Aniko and Wittmann, Jacquelyn and Grahl, Justin and Aldakkak, Mohammed and Thalji, Samih Z and McFall, Thomas and Kurzrock, Razelle and George, Ben and Kamgar, Mandana},
  title = {MEK inhibitor–based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag040}
}
Kostenlos starten →